Evidence map›Paper›PMID 24500500›Full record

ArticleEpigenetics2014

Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens: correlation with physiological and pathological characteristics, and with biomarkers of one-carbon metabolism.

Fabio Coppedè, Francesca Migheli, Angela Lopomo, Alessandra Failli, Annalisa Legitimo, Rita Consolini, Gabriella Fontanini, Elisa Sensi, Adele Servadio, Massimo Seccia and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Relationship Between Human mutL Homolog 1 (hMLH1) Hypermethylation and Colorectal Cancer: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Pooled it
  2. Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase in colorectal cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  3. Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  4. Review
  5. Article
  6. IncreasedMolecular & cellular oncology · 2025
    Article
  7. Epigenetic differences in the tumor suppressor genesInnovative surgical sciences · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. Advancing to the era of cancer immunotherapy.Cancer communications (London, England) · 2021
    Review
  12. Article
  13. Article
  14. Investigation ofFrontiers in molecular neuroscience · 2020
    Article
  15. Article
  16. Association of Polymorphisms in Genes Involved in One-Carbon Metabolism withInternational journal of molecular sciences · 2019
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Fabio CoppedèDepartment of Translational Research and New Technologies in Medicine and Surgery; Division of Medical Genetics; University of Pisa; Pisa, Italy; Istituto Toscano Tumori (ITT); Florence, Italy; Research Center Nutraceuticals and Food for Health-Nutrafood; University of Pisa; Pisa, Italy.
Francesca MigheliDepartment of Translational Research and New Technologies in Medicine and Surgery; Division of Medical Genetics; University of Pisa; Pisa, Italy; Istituto Toscano Tumori (ITT); Florence, Italy.
Angela LopomoDepartment of Translational Research and New Technologies in Medicine and Surgery; Division of Medical Genetics; University of Pisa; Pisa, Italy; Doctoral School in Genetics, Oncology, and Clinical Medicine; University of Siena; Siena, Italy.
Alessandra FailliIstituto Toscano Tumori (ITT); Florence, Italy; Department of Clinical and Experimental Medicine; University of Pisa; Pisa, Italy.
Annalisa LegitimoDepartment of Clinical and Experimental Medicine; University of Pisa; Pisa, Italy.
Rita ConsoliniDepartment of Clinical and Experimental Medicine; University of Pisa; Pisa, Italy.
Gabriella FontaniniDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Elisa SensiDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Adele ServadioDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Massimo SecciaDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Giuseppe ZoccoDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Massimo ChiarugiDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Roberto SpisniDepartment of Surgery, Medical, Molecular, and Critical Area Pathology; University of Pisa; Pisa, Italy.
Lucia MiglioreDepartment of Translational Research and New Technologies in Medicine and Surgery; Division of Medical Genetics; University of Pisa; Pisa, Italy; Istituto Toscano Tumori (ITT); Florence, Italy; Research Center Nutraceuticals and Food for Health-Nutrafood; University of Pisa; Pisa, Italy.
University of Pisa · ITMedical Genetics Center · DETumour Institute of Tuscany · ITPediatrics and Genetics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the promoter methylation levels of the APC, MGMT, hMLH1, RASSF1A and CDKN2A genes in 107 colorectal cancer (CRC) samples and 80 healthy adjacent tissues. We searched for correlation with both physical and pathological features, polymorphisms of folate metabolism pathway genes (MTHFR, MTRR, MTR, RFC1, TYMS, and DNMT3B), and data on circulating folate, vitamin B12 and homocysteine, which were available in a subgroup of the CRC patients. An increased number of methylated samples were found in CRC respect to adjacent healthy tissues, with the exception of APC, which was also frequently methylated in healthy colonic mucosa. Statistically significant associations were found between RASSF1A promoter methylation and tumor stage, and between hMLH1 promoter methylation and tumor location. Increasing age positively correlated with both hMLH1 and MGMT methylation levels in CRC tissues, and with APC methylation levels in the adjacent healthy mucosa. Concerning gender, females showed higher hMLH1 promoter methylation levels with respect to males. In CRC samples, the MTR 2756AG genotype correlated with higher methylation levels of RASSF1A, and the TYMS 1494 6bp ins/del polymorphism correlated with the methylation levels of both APC and hMLH1. In adjacent healthy tissues, MTR 2756AG and TYMS 1494 6bp del/del genotypes correlated with APC and MGMT promoter methylation, respectively. Low folate levels were associated with hMLH1 hypermethylation. Present results support the hypothesis that DNA methylation in CRC depends from both physiological and environmental factors, with one-carbon metabolism largely involved in this process.

Indexed as

DNA MethylationMetabolic Networks and PathwaysPromoter Regions, GeneticAgedAged, 80 and overBiomarkersCase-Control StudiesColonColorectal NeoplasmsFemaleFolic AcidHomocysteineHumansIntestinal MucosaMaleMiddle AgedBiomarkersFolic AcidHomocysteineVitamin B 12APCCDKN2AColorectal CancerDNA methylationepigeneticsfolate metabolismhMLH1MGMTpolymorphismsRASSF1A

Identifiers

PMID24500500
PMCPMC4121372
OpenAlexW2069289315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.